%0 Journal Article
%T Should we use the oral selective IP receptor agonist selexipag off
%A Georg Hansmann
%A Martin Koestenberger
%J Pulmonary Circulation
%@ 2045-8940
%D 2018
%R 10.1177/2045894018793580
%X We discuss the currently available data on the use of the prostacyclin mimetic selexipag in children and adolescents with pulmonary arterial hypertension (PAH). Future indications may include transitioning from intravenous prostacyclin/prostacyclin analog to oral selexipag, and vice versa, or adding selexipag as a third oral PAH-targeted agent in children not responding well to dual PAH therapy
%K Pediatric
%K prostacyclin receptor agonist
%K pulmonary arterial hypertension
%K selexipag
%U https://journals.sagepub.com/doi/full/10.1177/2045894018793580